Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 419
Selected: 0
NCT IDTitle
NCT04846634Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
NCT06700395A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
NCT05867563Clinical Trial Evaluating the Safety of the TQB2103 for Injection
NCT05353179Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
NCT03624309Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer
NCT01926288Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B
NCT03910127Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)
NCT05735496Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
NCT04144855A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection
NCT02649361Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
NCT04796623A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
NCT06767800A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
NCT06561607A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06738979A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
NCT06126562A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects
NCT07043751A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
NCT06649656A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
NCT06929195Clinical Trial to Evaluate the Tolerance of TQB2210 Injection
NCT05198505Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
NCT04405505A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
NCT07044908TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT02461407Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
NCT04326348A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)
NCT05252078Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
NCT04275050A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets
NCT06451640A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps
NCT05130515Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.
NCT06748079A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
NCT05645315Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
NCT07260708Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
NCT06859931Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06725641Bioequivalence Study of Methacholine for Inhalation (pharmacodynamics)
NCT03754244A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics
NCT04207463A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
NCT06218771A Study of TQB3454 Tablets in Patients With Blood Tumors
NCT01806376A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics
NCT06754891Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT04398953A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
NCT04373967Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
NCT07003074A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT06031480Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
NCT06897579Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
NCT05997342A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor
NCT03850873A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
NCT04385550A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
NCT07147946Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT04278820A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)
NCT06297642TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
NCT03799601Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC
NCT04955834A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes